Module CC-27 · Version 1.0
Therapeutic Drug Monitoring
Evaluate whether a therapeutic drug concentration was collected at the right time and can answer the monitoring question.
Your next section
Start section 1Read without an account. Sign in to save.
Who this module is for
Medical laboratory scientists and laboratory professionals working with therapeutic drug monitoring results.
Learning objectives
- Distinguish peak, trough, random, and area-under-the-curve approaches.
- Explain steady state, half-life, distribution, protein binding, and active metabolites.
- Recognize mistimed, contaminated, post-dose-line, or assay-interfered specimens.
How completion works
Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.
Sources
14 sources
1. MedlinePlus/NLM. Therapeutic Drug Monitoring. National Library of Medicine lab test information page.
Source note · laboratory reference
2. Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious MRSA Infections: revised consensus guideline. Am J Health-Syst Pharm. 2020;77:835-864.
Source note · laboratory reference
3. Kang JS, Pena V. Gentamicin. StatPearls. NCBI Bookshelf, updated 2024.
Source note · laboratory reference
4. FDA-approved prescribing information for digoxin tablets. DailyMed.
Source note · laboratory reference
5. Therapeutic drug monitoring of digoxin: impact of endogenous and exogenous digoxin-like immunoreactive substances. PubMed indexed review.
Source note · laboratory reference
6. FDA 510(k) substantial equivalence decision summary for digoxin immunoassay after digoxin immune Fab.
Source note · laboratory reference
7. FDA-approved prescribing information for phenytoin. DailyMed.
Source note · laboratory reference
8. Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin concentrations. PMC.
Source note · laboratory reference
9. FDA-approved prescribing information for lithium carbonate.
Source note · laboratory reference
10. Mayo Clinic Laboratories Carbamazepine Profile, Serum, and manufacturer immunoassay cross-reactivity documentation.
Source note · laboratory reference
11. Measurement of whole blood tacrolimus by LC-MS/MS and immunoassay methods. J Appl Lab Med. 2025.
Source note · laboratory reference
12. Effect of monitoring drug concentrations through lines used to administer the drugs: an in vitro study. PubMed indexed.
Source note · laboratory reference
13. 42 CFR 493.1291(g), Standard: Test report, critical or panic value notification.
Source note · laboratory reference
14. College of American Pathologists. All Common Checklist, COM.30000 Critical Result Notification (Phase II). CAP Accreditation Program, 12.09.2025 edition. College of American Pathologists. All Common Checklist, COM.30100 Critical Result Read-Back (Phase I). CAP Accreditation Program, 12.09.2025 edition.
Source note · accreditation standard